Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | KIF11 | P52732 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088597 | 0.90 | CES2 (0.64) | ALDH1A1TSHRKIF11CES2CES1 | |
| SCHEMBL28668106 | 0.82 | ALDH1A1 (0.54) | ALDH1A1TSHRKIF11NPC1RAB9A | |
| SCHEMBL22946411 | 0.82 | ALDH1A1 (0.54) | ALDH1A1TSHRKIF11NPC1RAB9A | |
| SCHEMBL2834217 | 0.82 | CES2 (0.83) | ALDH1A1TSHRKIF11NPC1RAB9A | |
| SCHEMBL1781341 | 0.82 | SRD5A2 (0.77) | ALDH1A1TSHRNPC1RAB9ACES2 | |
| SCHEMBL8177 | 0.78 | CES1 (0.40) | ALDH1A1TSHRNPC1RAB9ACES2 | |
| SCHEMBL13019489 | 0.77 | SRD5A2 (0.69) | ALDH1A1KIF11NPC1RAB9ACES2 | |
| SCHEMBL779220 | 0.77 | NPC1 (0.56) | ALDH1A1TSHRKIF11NPC1RAB9A | |
| SCHEMBL8494070 | 0.77 | GRIN2B (0.54) | ALDH1A1TSHRKIF11NPC1RAB9A | |
| SCHEMBL22130998 | 0.77 | PTPN1 (0.71) | ALDH1A1NPC1RAB9ACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576574-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | Sarepta Therapeutics, Inc. (US) | 2013-04-10 | — | — | EP | claimed |
| WO-2012031243-A2 | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | AVI BIOPHARMA, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| WO-2011150408-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | AVI BIOPHARMA, INC. (US) | 2011-12-01 | — | — | WO | claimed |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11225662-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11071749-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11072793-B2 | DsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210139896-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-05-13 | — | — | US | disclosed |
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| CN-107693797-B | Peptide oligonucleotide conjugates | 萨勒普塔医疗公司 | 2021-05-11 | — | — | CN | disclosed |
| US-20200277598-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-09-03 | — | — | US | disclosed |
| US-20130288369-A1 | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2013086441-A2 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013086444-A2 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-2576574-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | Sarepta Therapeutics, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| WO-2012150960-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
| WO-2012031243-A2 | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | AVI BIOPHARMA, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011150408-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | AVI BIOPHARMA, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | ALDH1A1 2803/4885TSHR 2993/4885KIF11 2391/4885 |
| US-20200277598-A1 | Peptide Oligonucleotide Conjugates | SNRPE, SMN1; SMN2, UPF1 | ALDH1A1 3700/4885TSHR 721/4885KIF11 2968/4885 |
| US-11071749-B2 | Oligonucleotide analogues targeting human LMNA | LMNB2, LMNA, LMNB1 | ALDH1A1 4394/4885TSHR 1863/4885KIF11 2132/4885 |
| US-20210139896-A1 | Peptide Oligonucleotide Conjugates | SNRPE, SMN1; SMN2, UPF1 | ALDH1A1 3700/4885TSHR 721/4885KIF11 2968/4885 |
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | ALDH1A1 2803/4885TSHR 2993/4885KIF11 2391/4885 |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SNRPE, SMN1; SMN2, UPF1 | ALDH1A1 3700/4885TSHR 721/4885KIF11 2968/4885 |
| US-11225662-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | ALDH1A1 3700/4885TSHR 721/4885KIF11 2968/4885 |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | ALDH1A1 3700/4885TSHR 721/4885KIF11 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.